TrialNature medicine2020

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.

Bruno Bockorny et al.PubMed ↗Publisher ↗

No numbers read from the abstract.